The END Fund

What The END Fund does

The END Fund is a 501(c)(3) collaborative philanthropy organization founded in 2012 and headquartered in New York, with additional hubs in London and Nairobi. The organization manages a portfolio of four programmatic funds — the Flagship Fund, Deworming Innovation Fund (launched 2020), Reaching the Last Mile Fund (launched 2017), and ARISE Fund — dedicated to controlling and eliminating six neglected tropical diseases (intestinal worms, schistosomiasis, lymphatic filariasis, river blindness, trachoma, and visceral leishmaniasis) that collectively affect approximately 1.4 billion people globally.

The Fund's operating model is to pool philanthropic capital from 25+ anchor investors (including the Bill & Melinda Gates Foundation, Legatum Foundation, Reaching the Last Mile/UAE Presidential Court, Children's Investment Fund Foundation, Helmsley Charitable Trust, Mackenzie Scott, and UK Aid) and coordinate drug donations from MSD, GSK, Pfizer, Merck KGaA, and Johnson & Johnson. These resources are channeled through a network of over 50 programmatic partners (Amref Health Africa, Helen Keller Intl, FHI 360, Sightsavers, The Carter Center, RTI International) and government health ministries in 31 countries across Africa, the Middle East, South Asia, and South America to deliver mass drug administration campaigns, surgeries, and health worker training.

The Fund has delivered 2.4 billion treatments cumulatively since 2012, including 240 million people treated in 2025 alone, and reports $4.48 billion in cumulative treatment value, 238,784 surgeries performed, and 8.33 million health workers trained. Revenue mechanics rely on multi-year anchor commitments with annual billing cadence rather than transactional giving. The Fund is not a technology company but operates an Interactive Data Visualization Tool and uses precision mapping for disease targeting. As a 501(c)(3) nonprofit, it has no equity ownership structure and is not backed by venture capital or private equity investors.

Name

The END Fund

Legal name

The END Fund Inc.

Website

https://endfund.org

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

51–100 employees

Short description

The END Fund is a 501(c)(3) collaborative philanthropy organization managing four programmatic funds that pool philanthropic capital and pharmaceutical drug donations to support mass drug administration, surgeries, and health worker training against six neglected tropical diseases across 31 countries.

Ownership category

akta.pro rank

Product category

Global Health Philanthropy

NAICS

Grantmaking Foundations (813211), Grantmaking and Giving Services (8132), Grantmaking and Giving Services (81321), Voluntary Health Organizations (813212)

SIC

Services-Social Services (8300)

akta.pro industry

PRIMARYBPAGAKAE

Public Charities & Grantmaking Intermediaries

Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking

SECONDARYHLAJAOAC

Global Health Financing Mechanisms & Pooled Funds

Healthcare & Life Sciences/Public Health, Government & Regulators/Global Health Initiatives & Partnerships

SECONDARYHLAJAKAC

Global Health Financing Mechanisms

Healthcare & Life Sciences/Public Health, Government & Regulators/Global Health & Development Agencies (NGOs/Multilaterals)

SECONDARYHLAJAMAC

Public Health Financing, Budgeting & Grants Management

Healthcare & Life Sciences/Public Health, Government & Regulators/Public Health Policy & Administration

SECONDARYHLAJALAF

Community Health & Prevention Program Funding

Healthcare & Life Sciences/Public Health, Government & Regulators/Public Health Funding, Grants & Program Administration

SECONDARYHLAJALAJ

Chronic Disease & Health Promotion Program Funding

Healthcare & Life Sciences/Public Health, Government & Regulators/Public Health Funding, Grants & Program Administration

SECONDARYFSANAJAI

Healthcare Access & Life Sciences Impact Funds

Financial & Insurance/Private Equity & Venture Capital/Impact / ESG & Sustainable Investment Funds

Keywords

• Philanthropic fund management
• Neglected tropical diseases
• Mass drug administration
• Disease elimination programs
• Collaborative philanthropy

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

1. Philanthropic Donations and Grants: The END Fund raises resources from a community of dedicated philanthropic investors and donors. The organization mobilizes private capital to support country-led NTD programs. Donors include foundations, family philanthropists, corporations, and government aid agencies. The fund model enables pooling of resources to maximize impact.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels8 records

Core offering

The END Fund is a collaborative philanthropy fund that pools private capital and donated pharmaceuticals to finance country-led mass drug administration campaigns, surgeries, and health worker training targeting six neglected tropical diseases (intestinal worms, schistosomiasis, lymphatic filariasis, river blindness, trachoma, and visceral leishmaniasis). It works through a network of 50+ NGO implementation partners and government health ministries across 31 countries to deliver treatments at scale.

Product overview

The END Fund is a collaborative philanthropy organization managing a portfolio of four programmatic funds dedicated to eliminating six neglected tropical diseases (intestinal worms, schistosomiasis, lymphatic filariasis, river blindness, trachoma, and visceral leishmaniasis). The core products are the Flagship Fund (cornerstone fund for mass drug administration), Deworming Innovation Fund (innovative deworming techniques in 4 countries), Reaching the Last Mile Fund (elimination of river blindness and lymphatic filariasis in Africa), and ARISE Fund (government co-financing and capacity building in 5 countries). The organization also offers an Interactive Data Tool for visualizing NTD burden and treatment data. The funds work by pooling private capital and partnering with governments, pharmaceutical companies, and programmatic partners to deliver treatments, perform surgeries, and train health workers.

Differentiator

Problem solved

Functional benefit

Brands

• Flagship Fund: The END Fund's cornerstone fund working to treat and prevent five neglected tropical diseases through mass drug administration campaigns, surgeries, and health worker training.
• Deworming Innovation Fund
• Reaching the Last Mile Fund
• ARISE Fund

Products and services

• Flagship Fund The END Fund's cornerstone fund that works to treat and prevent five neglected tropical diseases (intestinal worms, schistosomiasis, lymphatic filariasis, river blindness, and trachoma) through mass drug administration campaigns, surgeries, health worker training, and prevention education. Available for philanthropic investment by foundations, family offices, corporates, and government aid agencies.
• Deworming Innovation Fund A fund that pilots innovative techniques to stop the spread of schistosomiasis and intestinal worms through precision mapping, expanded treatment to adults, nutrition programming, and WASH programs in Ethiopia, Kenya, Rwanda, and Zimbabwe. Designed for philanthropic investors seeking innovative approaches to parasitic worm elimination.
• Reaching the Last Mile Fund A multi-donor initiative established by the UAE Presidential Court and the Bill & Melinda Gates Foundation to eliminate river blindness and lymphatic filariasis across 39 African countries. Open to multi-donor philanthropic investment for continent-wide disease elimination.
• ARISE Fund

Quantifiable outcome

• 240 million people treated in 2025
• +6 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Twelve partnerships are on record, tiered core/anchor, core and supporting.

• World Health Organization (WHO)core/anchorStrategic or Co-development PartnerKEY: WHO provides technical guidance, guidelines for NTD elimination, and verification of elimination status. The END Fund aligns its programs with WHO's NTD Roadmap 2021-2030.
• Amref Health Africacore/anchorStrategic or Co-development PartnerMajor programmatic partner operating in multiple countries. Supports END Fund programs including visceral leishmaniasis treatment in East Africa, trachoma elimination in Ethiopia, and intestinal worm/schistosomiasis mapping in Kenya.
• Helen Keller IntlcoreStrategic or Co-development PartnerProgrammatic partner supporting NTD treatment and prevention programs globally.
• FHI 360coreStrategic or Co-development PartnerProgrammatic partner providing technical expertise and implementation support for NTD programs.
• SightsaverscoreStrategic or Co-development PartnerProgrammatic partner focused on eliminating trachoma and other NTDs, particularly in West Africa.
• The Carter CentercoreStrategic or Co-development PartnerProgrammatic partner with long history in NTD control, particularly river blindness elimination efforts.
• RTI InternationalcoreStrategic or Co-development PartnerProgrammatic partner providing technical and implementation support for NTD programs.
• CBMsupportingStrategic or Co-development PartnerProgrammatic partner supporting disability-inclusive development and NTD programs.
• Liverpool School of Tropical MedicinesupportingStrategic or Co-development PartnerAcademic partner providing research and technical expertise in NTD control and elimination.
• MITOSATHsupportingStrategic or Co-development PartnerProgrammatic partner operating in Nigeria, supporting deworming and schistosomiasis treatment programs.
• Africa CDCsupportingStrategic or Co-development PartnerIn June 2025, Africa CDC partnered with END Fund and WHO to establish a digital portal for NTD planning and data sharing across 50 African countries.
• International Trachoma Initiative (ITI)coreStrategic or Co-development PartnerCoordinates delivery of azithromycin donated by Pfizer through the Zithromax shipment tracker for trachoma elimination.

Scale indicators10 records

Recent moves11 records

Expansion highlights6 records

Broad incumbents

• Clinton Health Access Initiative (CHAI): Global health organization that works with governments and partners to strengthen health systems and improve access to medicines in low- and middle-income countries. Comparable as a large-scale philanthropic intermediary driving NTD and related disease programs across Africa and Asia.
• Global Fund to Fight AIDS, Tuberculosis and Malaria: Large-scale global health financing partnership pooling government and private resources to combat three major infectious diseases. Directly comparable as a multi-donor pooled fund model delivering treatments through country-led programs with WHO alignment.
• Gavi, the Vaccine Alliance: Global pooled fund that mobilizes public and private capital to deliver vaccines at scale to lower-income countries. Comparable as a public-private pooled financing mechanism that aggregates donor capital and partners with pharma and governments for last-mile health delivery.
• Wellcome Trust: Large UK-based charitable foundation funding global health research and infectious disease programs including NTDs. Comparable as a major global health philanthropic funder operating at a similar scale to END Fund's anchor investors.

Direct peers

• Helen Keller International: Global health NGO working on NTD treatment, vision, and nutrition programs in low-income countries. Listed as a core programmatic partner of END Fund and shares the same target populations and country footprint.
• The Carter Center: Humanitarian organization founded by former US President Jimmy Carter with major river blindness and trachoma elimination programs across Africa and the Americas. Listed as a programmatic partner of END Fund and operates a directly comparable disease elimination model.
• International Trachoma Initiative (ITI): Dedicated program coordinating Pfizer's Zithromax donations for trachoma elimination across 40+ countries. Listed as a core programmatic partner of END Fund and operates a directly comparable single-disease pooled-distribution model.
• Sightsavers: International NGO that prevents avoidable blindness and advocates for disability rights, with significant NTD programming in trachoma and river blindness across Africa and Asia. A direct programmatic partner of END Fund and one of its closest operating peers.
• Drugs for Neglected Diseases initiative (DNDi): Collaborative, patient-needs driven R&D organization developing new treatments for neglected diseases including leishmaniasis and helminth infections. Comparable as a global health pooled-fund-style organization focused on NTDs but oriented to drug development rather than delivery.
• Children's Investment Fund Foundation (CIFF): Major philanthropic foundation that supports NTD deworming and elimination programs globally, including as a major anchor investor in END Fund. Comparable as a large, strategic philanthropy funding the same deworming and NTD elimination outcomes.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/endfund
• Facebookfacebook.com/endfund
• LinkedInlinkedin.com/company/the-end-fund
• Instagraminstagram.com/the_endfund
• Xx.com/theendfund

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The END Fund